Blueprint Medicines Surges to 88th Most Traded Stock Amid Sanofi Acquisition

On June 9, 2025, Blueprint Medicines (BPMC) saw a significant surge in trading volume, with a turnover of $919 million, marking a 134.31% increase from the previous day. This substantial rise in trading activity positioned Blueprint Medicines as the 88th most traded stock of the day.

Sanofi, a leading healthcare company, has announced its intention to acquire Blueprint Medicines for over $9 billion. This acquisition is part of Sanofi's strategy to expand its portfolio in rare immunological diseases and to add an early-stage pipeline in immunology. Blueprint Medicines specializes in systemic mastocytosis, a rare immunological disease, and the acquisition includes a drug approved in the U.S. and the EU for this condition.

The proposed sale of Blueprint Medicines has sparked investigations into the adequacy of the price and process by legal firms such as Kahn Swick & Foti, LLC and Johnson Fistel, PLLP. These investigations aim to ensure that the board members of Blueprint Medicines have acted in the best interests of the shareholders.

Sanofi's acquisition of Blueprint Medicines is seen as a bullish signal for biotech mergers and acquisitions. The deal highlights the growing interest in rare immunological diseases and the potential for significant growth in this sector. The acquisition is expected to strengthen Sanofi's position in the biotech industry and provide it with a robust pipeline of innovative treatments.